Identity recordUS research-market identity with a separate FDA-approved medicine record
What PT-141 / Bremelanotide resolves to
This record resolves seller-labelled 10 mg PT-141 research listings. VYLEESI is a separate FDA-approved bremelanotide prescription product with a 1.75 mg presentation, defined indication, label, and regulated supply chain. The research listings do not inherit that approval.
- Evidence lane
- Research price board
- Current record
- 2 of 3 rows in stock
- Checked
- Jul 23, 2026
PT 141BremelanotideVyleesi
Destination recordHealth Canada warning
What Canada still has to prove
A Canada-specific verification guide built around Health Canada’s peptide warning, the Drug Product Database, and provincial pharmacy licensing.
- Comparison mode
- DIN / pharmacy / CAD cost
- Price coverage
- No sellers ranked
- Guide updated
- July 18, 2026